首页 > 市场调查报告书 > 製药

骨疾病

市场调查报告书

商品编码

1738717

2026-2032 年骨关节炎药物市场（依治疗类型、给药途径、通路及地区划分）

Osteoarthritis Therapeutics Market By Treatment Type, Route of Administration, Distribution Channel, & Region for 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

骨关节炎药物市场估值（2026-2032）

推动骨关节炎药物市场扩张的主要因素包括老年人口的成长、研发活动的活性化以及骨关节炎药物的资金筹措。预计2024年市场规模将超过91.3亿美元，2032年估值将达到约178亿美元。

预计随着人们知识水平的提高、更优治疗方法的普及以及寻求治疗的意愿的增强，骨关节炎药物市场将进一步成长。骨关节炎也被认为是最常见的关节炎类型。骨关节炎药物需求的持续成长，将推动该市场在2026年至2032年间以8.70%的复合年增长率成长。

骨关节炎的高发生率是否会推动骨关节炎药物市场的发展？

骨关节炎盛行率的上升是推动骨关节炎药物市场发展的主要因素。骨关节炎是最常见的关节疾病之一，尤其在老年人群中发病，影响全球数百万人。随着人口老化，预计骨关节炎患者数量将会增加，从而增加对适当治疗方法的需求。患者数量的增加将导致对各种治疗方案的需求，以控制疼痛、减轻发炎和改善关节功能，这将扩大骨关节炎药物市场。此外，增加对骨关节炎及其对生活品质影响的认识将有助于更早诊断和治疗，从而促进市场成长。

此外，骨关节炎的高发生率促使人们积极研发，旨在开发新型、更有效的治疗方法。製药公司和研究机构正在致力于开发比标准非类固醇消炎剂和止痛药更有效的缓解疾病性骨关节炎药物 (DMOAD) 和生技药品製剂。基因疗法、再生医学和个体化医疗已成为骨关节炎管理领域的希望进展。此外，政府的科学研究措施和资金投入，以及新型诊断技术的日益普及，预计将提高治疗的有效性和可近性，从而推动骨关节炎药物市场的成长。

缺乏有效的治疗方法会影响骨关节炎药物市场的需求吗？

缺乏高效的骨关节炎 (OA)治疗方法会影响（但不一定会减少）对骨关节炎药物的需求。儘管缺乏明确的治疗方法或高效的长期治疗方法，但由于 OA 发病率高且需要对症状进行管理，因此 OA 药物市场仍然强劲。骨关节炎是一种慢性退化性疾病，影响全球数百万人。许多原因是人口老化和肥胖等生活习惯。由于发病率如此之高，因此需要不断治疗以缓解疼痛并增强关节功能，即使这些治疗方法只能提供短期或部分缓解。患者和医疗保健提供者一直在寻找新的、可能更有效的治疗方案，以确保市场需求持续成长。

此外，对症治疗的持续需求为市场持续改进和创新提供了可能性。製药和生技公司正在投资开发新型药物，包括缓解疾病的骨关节炎药物 (DMOAD)，旨在解决骨关节炎的根本病因，而非仅仅治疗症状。日益增长的需求正在推动替代疗法的发展，例如再生医学方法和个人化治疗。目前缺乏高效率的治疗方法代表着庞大的未满足医疗需求，同时也激励研发活动，刺激市场发展。总而言之，儘管目前治疗方法的疗效可能有限，但对骨关节炎药物持续成长的需求凸显了该领域持续创新和改进的迫切需求。

The osteoarthritis therapeutics market, are growing elderly population, increased research and development activities, and financing for osteoarthritis medicines are all key drivers of market expansion. The market size surpass USD 9.13 Billion valued in 2024 to reach a valuation of around USD 17.8 Billion by 2032.

People's increased knowledge, the availability of better treatment alternatives, and their willingness to seek therapy are projected to contribute to the growth of the osteoarthritis treatment market. It is also said that osteoarthritis is the most frequent type of arthritis. The rising demand for osteoarthritis therapeutics is enabling the market grow at a CAGR of 8.70% from 2026 to 2032.

Will the High Prevalence of Osteoarthritis Drive the Osteoarthritis Therapeutics Market?

The rising prevalence of osteoarthritis is a major factor driving the Osteoarthritis Therapeutics Market. Osteoarthritis is one of the most common joint illnesses, especially among older persons, affecting millions globally. As populations age, the number of people suffering from osteoarthritis is predicted to climb, creating a greater demand for appropriate treatment alternatives. This growing patient population demands a variety of treatments to control pain, reduce inflammation, and improve joint function, which will expand the market for osteoarthritis medications. Furthermore, increased knowledge of osteoarthritis and its influence on quality of life leads to earlier diagnosis and treatment, which fuels market growth.

Furthermore, the high frequency of osteoarthritis encourages significant research and development efforts targeted at developing novel and more effective therapies. Pharmaceutical companies and research organizations are working to produce disease-modifying osteoarthritis medicines (DMOADs) and biologics that are more effective than standard NSAIDs and analgesics. Gene therapy, regenerative medicine, and customized medicine are emerging as promising advances in osteoarthritis management. Furthermore, government initiatives and funding for research, as well as increased availability of new diagnostic technologies, are projected to improve treatment efficacy and accessibility, consequently driving the growth of the osteoarthritis therapeutics market.

Will the Lack of Effective Treatments Impact the Demand for the Osteoarthritis Therapeutics Market?

The lack of very effective treatments for osteoarthritis (OA) has an impact on demand for osteoarthritis medicines, although it does not necessarily reduce it. Despite the lack of a definite cure or highly effective long-term treatment, the market for OA therapies remains strong due to the condition's widespread incidence and the necessity for symptom management. Osteoarthritis is a chronic, degenerative illness that affects millions of people worldwide. It is mostly caused by aging populations and lifestyle factors like obesity. This high prevalence ensures a consistent need for treatments that can relieve pain and enhance joint function, even if they only provide short or partial relief. Patients and healthcare providers are constantly looking for new and perhaps more effective choices, ensuring a sustained market demand.

Furthermore, the continual requirement for symptom management opens up the potential for incremental market improvements and innovation. Pharmaceutical and biotechnology companies are investing in the development of novel medications, including disease-modifying osteoarthritis drugs (DMOADs), with the goal of addressing the underlying causes of OA rather than simply treating symptoms. The increased demand encourages the development of alternative remedies, such as regenerative medicine approaches and tailored treatments. While the current absence of highly effective medications demonstrates a major unmet medical need, it also motivates research and development activities, keeping the market active. In conclusion, while the efficacy of current treatments may be limited, the continuing and growing demand for osteoarthritis medications highlights the important need for ongoing innovation and improvement in this sector.

Category-Wise Acumens

Will the Widespread Use of Medications Drive the Pharmaceuticals Segment for the Osteoarthritis Therapeutics Market?

The widespread usage of drugs is a significant driving force in the Osteoarthritis Therapeutics Market's pharmaceutical segment. As osteoarthritis is one of the most common chronic joint conditions worldwide, there is a high demand for effective symptom management. Nonsteroidal anti-inflammatory medications (NSAIDs), analgesics, and corticosteroids are routinely used to treat the principal symptoms of osteoarthritis: pain and inflammation. The efficacy of these treatments in giving instant relief makes them a cornerstone in disease care, fueling steady demand in the pharmaceutical sector.

Furthermore, the development of improved pharmacological treatments, such as disease-modifying osteoarthritis medications (DMOADs), is expected to boost the pharmaceutical industry. DMOADs are intended not just to treat symptoms but also to change the underlying disease process, potentially reducing the progression of osteoarthritis. Another factor driving market expansion is pharmaceutical companies' increased expenditure in research & development to provide more effective and tailored medicines. Furthermore, the movement toward personalized medicine, which tailors' treatments to unique patient profiles, is gaining pace and is projected to boost innovation and broaden therapeutic alternatives. As healthcare professionals continue to prioritize enhancing the quality of life for osteoarthritis patients, the dependence on and progress of pharmaceutical therapies will remain a critical part in the overall market dynamics.

Will the Convenience and Compliance of the Oral Route Drive Significant Demand for the Osteoarthritis Therapeutics Market?

The convenience and compliance benefits of the oral route of administration are expected to fuel significant demand in the Osteoarthritis Therapeutics Market. Both patients and healthcare providers favor oral drugs because they are simple to use, non-invasive, and may be self-administered without the need for expert supervision. This choice is especially essential in controlling chronic illnesses such as osteoarthritis, where long-term treatment is frequently required. Nonsteroidal anti-inflammatory medicines (NSAIDs) and analgesics are common oral medications used to treat pain and inflammation caused by osteoarthritis. Their availability in various formulations, including extended-release tablets, improves patient compliance by reducing the frequency of doses, resulting in better adherence to specified treatment regimens.

Furthermore, the continued development of innovative oral medicines, such as disease-modifying osteoarthritis medications (DMOADs), is projected to help drive market expansion. Pharmaceutical companies are making significant R&D investments to produce more effective and safer oral drugs that can halt the progression of osteoarthritis and give greater symptom relief. Innovative drug delivery technologies, including targeted administration systems and combination medicines, are also improving the efficacy and acceptability of oral treatments. As a result, the combination of convenience, increased patient compliance, and developments in oral therapies is expected to considerably boost demand and expand the Osteoarthritis therapies Market in the years ahead.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in Europe Accelerate the Growth of the Osteoarthritis Therapeutics Market?

The ease and compliance of the oral mode of administration are expected to drive significant demand in the Osteoarthritis Therapeutics Market. Both patients and healthcare providers favor oral drugs because they are simple to use, non-invasive, and may be self-administered without the need for expert supervision. This choice is especially essential in controlling chronic illnesses such as osteoarthritis, where long-term treatment is frequently required. Nonsteroidal anti-inflammatory medicines (NSAIDs) and analgesics are common oral medications used to treat pain and inflammation caused by osteoarthritis. Their availability in various formulations, including extended-release tablets, improves patient compliance by reducing the frequency of doses, resulting in better adherence to specified treatment regimens.

Furthermore, the continued development of innovative oral medicines, such as disease-modifying osteoarthritis medications (DMOADs), is projected to help drive market expansion. Pharmaceutical companies are making significant investments in R&D to produce more effective and safer oral drugs that can halt the progression of osteoarthritis and give greater symptom relief. Innovative drug delivery technologies, including as targeted administration systems and combination medicines, are also improving the efficacy and acceptability of oral treatments. As a result, the combination of convenience, increased patient compliance, and developments in oral therapies is expected to considerably boost demand and expand the Osteoarthritis therapies Market in the years ahead.

Will the Rapidly Aging Population in the Asia Pacific Region Propel the Osteoarthritis Therapeutics Market?

The growing aging population in Asia-Pacific is expected to considerably drive the Osteoarthritis Therapeutics Market. As life expectancy rises, so will the prevalence of age-related illnesses such as osteoarthritis. Because of the natural wear and strain on joints over time, older persons are more vulnerable to osteoarthritis, making them a prime target for therapeutic approaches. Countries like Japan, China, and South Korea, which have among of the world's fastest-aging populations, are seeing an increase in osteoarthritis instances. This generational shift is driving a significant need for effective osteoarthritis treatments, which range from standard pain management to advanced disease-modifying medications.

Increased awareness of osteoarthritis and its impact on quality of life is prompting patients and healthcare providers to seek improved management choices. Many Asia-Pacific countries' healthcare infrastructures are improving, with better access to medical care and a greater emphasis on chronic disease management. This atmosphere promotes the use of new and innovative osteoarthritis medicines. Pharmaceutical companies are also realizing the possibility and investing in R&D to meet the growing demand. The Asia-Pacific region's large, aging population and improved healthcare capabilities position it as a prominent growth area for the Osteoarthritis Therapeutics Market, with significant opportunities for breakthroughs in treatment options and patient outcomes.

Competitive Landscape

The osteoarthritis therapeutics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the osteoarthritis therapeutics market include:

Pfizer Inc. (U.S.)
Abbvie Inc. (U.S.)
Novartis AG (Switzerland)
Amgen Inc. (U.S.)
Boehringer Ingelheim International GmbH. (Germany)
Samsung Bioepis. (South Korea)
Merck & Co Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Teva Pharmaceuticals Industries Ltd. (Israel)
AstraZeneca PLC (U.K.)
Zimmer Biomet (U.S.)
Stryker Corporation (U.S.)

Latest Developments

In March 2023, Remedium Bio, a biotech business in the United States, formed a strategic agreement with Exothera, a Belgian CDMO, to advance disease-modifying gene therapy for osteoarthritis, AAV2-FGF18. This effort intends to use expertise and resources to develop and expand the potential market presence of its revolutionary therapy.
In May 2023, Grunenthal disclosed that their investigational non-opioid medication, resiniferatoxin (RTX), which is now in Phase III clinical testing, has been granted breakthrough therapy designation by the US FDA for treating knee osteoarthritis pain. This recognition was driven by encouraging phase I and II clinical data, which demonstrated considerable pain alleviation and a favorable safety profile.
In January 2022Merck recently entered into an out-licensing arrangement with TrialSpark/High Line Bio in the United States, through its subsidiary Ares Trading SA. Currently, sprifermin is being research for its possible advantages in people suffering from OA

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Osteoarthritis Therapeutics Market, By Treatment Type

Pharmaceuticals:
Non-pharmaceuticals

5. Osteoarthritis Therapeutics Market, By Route of Administration

Oral
Topical
Intra-articular
Parenteral

6. Osteoarthritis Therapeutics Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

7. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

8. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

9. Competitive Landscape

Key Players
Market Share Analysis

10. Company Profiles

Pfizer Inc.
Johnson & Johnson
Sanofi
GlaxoSmithKline plc.
Abbott Laboratories
Novartis AG
Horizon Therapeutics plc.
Zimmer Biomet Holdings, Inc.
Bayer AG
Anika Therapeutics, Inc.

11. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

12. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026-2032 年骨关节炎药物市场（依治疗类型、给药途径、通路及地区划分）

Osteoarthritis Therapeutics Market By Treatment Type, Route of Administration, Distribution Channel, & Region for 2026-2032

骨关节炎药物市场估值（2026-2032）

骨关节炎的高发生率是否会推动骨关节炎药物市场的发展？

缺乏有效的治疗方法会影响骨关节炎药物市场的需求吗？

目录

第一章 引言

第二章执行摘要

第三章市场概述

第四章骨关节炎药物市场（依治疗类型）

第五章骨关节炎药物市场（依给药途径）

6. 骨关节炎药物市场（依分销管道）

第七章区域分析

第八章市场动态

第九章 竞争态势

第十章 公司简介

第十一章 市场展望与机会

第十二章 附录

Osteoarthritis Therapeutics Market Valuation - 2026-2032